Peytavin G - Search Results

1

Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.

Duong M, Piroth L, Peytavin G, Forte F, Kohli E, Grappin M, Buisson M, Chavanet P, Portier H. Duong M, et al. Among authors: peytavin g. Clin Infect Dis. 2001 Aug 1;33(3):386-92. doi: 10.1086/321876. Epub 2001 Jun 21. Clin Infect Dis. 2001. PMID: 11438909

2

Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens.

Duong M, Piroth L, Grappin M, Forte F, Peytavin G, Buisson M, Chavanet P, Portier H. Duong M, et al. Among authors: peytavin g. HIV Clin Trials. 2001 Mar-Apr;2(2):128-35. doi: 10.1310/M3JR-G390-LXCM-F62G. HIV Clin Trials. 2001. PMID: 11590521 Clinical Trial.

3

Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.

Chavanet P, Piroth L, Grappin M, Buisson M, Gourdon F, Cabié A, Duong M, Brunel-Dalmas F, Peytavin G, Portier H. Chavanet P, et al. Among authors: peytavin g. HIV Clin Trials. 2001 Sep-Oct;2(5):408-12. doi: 10.1310/afde-2byx-mdgl-n6mp. HIV Clin Trials. 2001. PMID: 11673815 Clinical Trial.

4

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: peytavin g. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.

5

Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F; Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Flandre P, et al. Among authors: peytavin g. Antivir Ther. 2002 Jun;7(2):113-21. Antivir Ther. 2002. PMID: 12212923 Clinical Trial.

6

Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.

Bernard L, Vuagnat A, Peytavin G, Hallouin MC, Bouhour D, Nguyen TH, Vildé JL, Bricaire F, Raguin G, de Truchis P, Ghez D, Duong M, Perronne C. Bernard L, et al. Among authors: peytavin g. Ann Intern Med. 2002 Oct 15;137(8):656-9. doi: 10.7326/0003-4819-137-8-200210150-00009. Ann Intern Med. 2002. PMID: 12379065

7

Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Yéni P; Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group. Launay O, et al. Among authors: peytavin g. Clin Infect Dis. 2002 Nov 1;35(9):1096-105. doi: 10.1086/342694. Epub 2002 Oct 15. Clin Infect Dis. 2002. PMID: 12384844 Clinical Trial.

8

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, Besnier JM, Chêne G, Raffi F, Brun-Vézinet F; APROCO Study Group. Masquelier B, et al. Among authors: peytavin g. J Infect Dis. 2002 Nov 15;186(10):1503-7. doi: 10.1086/344358. Epub 2002 Oct 23. J Infect Dis. 2002. PMID: 12404170

9

HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy.

Dupin N, Buffet M, Marcelin AG, Lamotte C, Gorin I, Ait-Arkoub Z, Tréluyer JM, Bui P, Calvez V, Peytavin G. Dupin N, et al. Among authors: peytavin g. AIDS. 2002 Dec 6;16(18):2419-24. doi: 10.1097/00002030-200212060-00006. AIDS. 2002. PMID: 12461415

10

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. Marcelin AG, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2003 Feb;47(2):594-600. doi: 10.1128/AAC.47.2.594-600.2003. Antimicrob Agents Chemother. 2003. PMID: 12543665 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters